Nautilus Biotechnology, Inc.NAUTNASDAQ
LOADING
|||

Analyst Sentiment

Analysts are neutral — opinion is divided on direction.

Consensus Rating
Hold
4 analysts·Low coverage
50%
Rating Distribution
Strong Buy
00%
Buy
250%
Hold
125%
Sell
125%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see moderate upside — consensus target 28% higher.

Bear Case
$2.50
+28%
Consensus
$2.50
+28%
Bull Case
$2.50
+28%
Price Range4 analysts
Low
Consensus
High
$2.50
$2.50
Current Target
Current Price
$1.95
Upside to Target
$0.55

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Feb 28, 2025Guggenheim
Nautilus Biotechnology price target lowered to $2.50 from $4 at Guggenheim
Target:$2.50
+92.3%from $1.30
Jun 27, 2024Guggenheim
Guggenheim Starts Nautilus Biotechnology (NAUT) at Buy
Target:$6.00
+162.6%from $2.29